register

Medical

Patients with private health insurance pay more for cancer treatment in Australia

Health Industry Hub | May 6, 2020 |

Patients with private health insurance are paying almost twice as much in out-of-pocket expenses for cancer treatment than those with no insurance, according to the authors of research published by the Medical Journal of Australia.

Researchers from the University of Western Australia have been following adults with colorectal, lung, prostate or breast cancer between 1 April 2014 and 31 April 2017.

Participants living in outer metropolitan areas experienced higher costs than participants in rural areas. Ninety-eight per cent of outer metropolitan and 95% of rural participants were out-of-pocket and the amount they paid varied between $13 and $106,140. The majority of participants’ out-of-pocket costs were due to gap payments for medical costs such as surgery, tests and doctor’s appointments.“

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“Among rural participants, mean out-of-pocket expenses were higher for men ($1,988 v $1,362 for women), for people with private health insurance ($2,455 v $1,103), and for people who were married ($2,086 v $1,297), had undergone surgery ($1,990 v $1,360), or had worked prior to being diagnosed with cancer ($2,084 v $1,298),” reported the authors, led by Professor Christobel Saunders.

“Among outer metropolitan participants, mean out-of-pocket expenses were higher for men ($5,217 v $2,247), for people with private health insurance ($4,670 v $2,510), and for those who had undergone surgery ($5,434 v $2,157), worked prior to being diagnosed with cancer ($5,471 v $2,143), resided in higher socioeconomic areas ($4299 v $1,859), or were receiving chemotherapy ($4,286 v $2,735).

“The higher out-of-pocket expenses for people with private health insurance or undergoing surgery indicate the importance of health care funding arrangements and the magnitude of the costs borne by patients,” Saunders and colleagues wrote.

“The marked variation in out-of-pocket expenses … highlights the need for easily accessible information about services, medical costs, and gap payments for all health care services.

“Problems that still need attention in the unregulated private fee-setting environment in Australia include price discrimination in some specialist sectors.

“Bundles of care for cancer treatment that would allow patients and their families to better understand and plan for expenses should be explored,” the authors concluded.


News & Trends - Biotechnology

Aussie biotech secures agreement with UQ and USyd to advance cardiovascular diseases research

Aussie biotech secures agreement with UQ and USyd to advance cardiovascular diseases research

Health Industry Hub | July 26, 2024 |

Biotech News: Australian biotechnology company, Cartherics, developing immune cell therapies for the treatment of cancer, has entered into a Technology […]

More


News & Trends - MedTech & Diagnostics

NSW Health Secretary urges more focus on patient experience, drawing from her own heart valve disease journey

NSW Health Secretary urges more focus on patient experience, drawing from her own heart valve disease journey

Health Industry Hub | July 26, 2024 |

In a heart-warming event that united patients, their loved ones, representatives from patient organisations and employees, Edwards Lifesciences hosted its […]

More


Human Resources

'To be an inclusive society, we need an embedded national strategy to combat systemic racism', says Commissioner Sivaraman

‘To be an inclusive society, we need an embedded national strategy to combat systemic racism’, says Commissioner Sivaraman

Health Industry Hub | July 26, 2024 |

Race Discrimination Commissioner Giridharan Sivaraman has welcomed the release of the Multicultural Framework Review by the Federal Government, calling it […]

More


News & Trends - Pharmaceuticals

New shingles vaccine is linked with lower risk of dementia

Shingles vaccine lowers risk of dementia

Health Industry Hub | July 26, 2024 |

Pharma News: A recombinant shingles vaccine which was added to Australia’s National Immunisation Program (NIP) in November last year, is […]

More


This content is copyright protected. Please subscribe to gain access.